Chelsea Therapeutics to Present at 9th Annual Needham Healthcare Conference

CHARLOTTE, N.C., June 3, 2010 (GLOBE NEWSWIRE) — Chelsea Therapeutics
International, Ltd. (Nasdaq:CHTP) is scheduled to present at the 9th Annual
Needham Healthcare Conference at 2:00 PM ET on Wednesday June 9, 2010 at the New
York Palace Hotel in New York City.

Dr. Simon Pedder, Chelsea’s president and chief executive officer, will provide
a brief overview of the company’s product pipeline, clinical development status
and upcoming milestones.

Dr. Pedder’s presentation will be webcast live and archived for 30 days on
Chelsea’s website, www.chelseatherapeutics.com.

About Chelsea Therapeutics

Chelsea Therapeutics is a biopharmaceutical development company that acquires
and develops innovative products for the treatment of a variety of human
diseases. Chelsea’s most advanced drug candidate, Northera(TM) (droxidopa), is
an orally active synthetic precursor of norepinephrine initially being developed
for the treatment of neurogenic orthostatic hypotension. In addition to
Northera, Chelsea is also developing a portfolio of metabolically inert oral
antifolate molecules engineered to have potent anti-inflammatory and anti-tumor
activity to treat a range of immunological disorders, including two clinical
stage product candidates: CH-1504 and CH-4051. Preclinical and clinical data
suggest superior safety and tolerability, as well as increased potency versus
methotrexate (MTX).

This press release contains forward-looking statements regarding future events.
These statements are just predictions and are subject to risks and uncertainties
that could cause the actual events or results to differ materially. These risks
and uncertainties include risks and costs of drug development, risk of
regulatory approvals, our reliance on our lead drug candidates droxidopa and
CH-4051, reliance on collaborations and licenses, intellectual property risks,
our need to raise additional operating capital in the future, our history of
losses, competition, market acceptance for our products if any are approved for
marketing, and reliance on key personnel including specifically Dr. Pedder.

CONTACT: Chelsea Therapeutics
Investor/Media Relations
Kathryn McNeil
718-788-2856

Chelsea Therapeutics to Host Conference Call to Discuss Fourth Quarter and Full Year…

Chelsea Therapeutics to Host Conference Call to Discuss Fourth Quarter and Full
Year 2009 Results

CHARLOTTE, N.C., March 3, 2010 (GLOBE NEWSWIRE) — Chelsea Therapeutics
International, Ltd. (Nasdaq:CHTP) announced that it will release fourth quarter
and full year results for the period ended December 31, 2009 after the market
closes on Wednesday, March 10, 2010. Chelsea management will host a conference
call and live webcast to discuss these financial results and provide an update
on each of its development programs that afternoon at 4:30 PM ET.

Interested investors may participate in the conference call by dialing
877-638-9567 (domestic) or 720-545-0009 (international). A replay will be
available for one week following the call by dialing 800-642-1687 for domestic
participants or 706-645-9291 for international participants and entering
passcode 60600587 when prompted. Participants may also access both the live and
archived webcast of the conference call on Chelsea’s web site at
www.chelseatherapeutics.com.

About Chelsea Therapeutics

Chelsea Therapeutics is a biopharmaceutical development company that acquires
and develops innovative products for the treatment of a variety of human
diseases. Chelsea’s most advanced drug candidate, Droxidopa, is an orally active
synthetic precursor of norepinephrine initially being developed for the
treatment of neurogenic orthostatic hypotension. In addition to Droxidopa,
Chelsea is also developing a portfolio of metabolically inert oral antifolate
molecules engineered to have potent anti-inflammatory and anti-tumor activity to
treat a range of immunological disorders, including two clinical stage product
candidates: CH-1504 and CH-4051. Preclinical and clinical data suggest superior
safety and tolerability, as well as increased potency versus methotrexate (MTX).

This press release contains forward-looking statements regarding future events.
These statements are just predictions and are subject to risks and uncertainties
that could cause the actual events or results to differ materially. These risks
and uncertainties include reliance on collaborations and licenses, risks and
costs of drug development, regulatory approvals, intellectual property risks,
our reliance on our lead drug candidate CH-1504, our history of losses and need
to raise more money, competition, market acceptance for our products if any are
approved for marketing, reliance on key personnel including specifically Dr.
Pedder, management of rapid growth, and the need to acquire or develop
additional products.

CONTACT: Chelsea Therapeutics
Investors & Media:
Kathryn McNeil
718-788-2856
mcneil@chelseatherapeutics.com

How long-lasting memories form in the brain

Washington, Aug 12 (ANI): A research team, led by Indian-origin boffin, has come closer to understanding how fleeting moments are sealed into life-long memories.

According to the researchers, the findings may one day help scientists develop treatments to prevent and treat conditions such as post-traumatic stress disorder.

“Although many things are known about memories that form from repeat experiences, not much is known with regard to how some memories form with just one exposure,” said Ashok Hegde, from Wake Forest University School of Medicine and the lead investigator on the study.

Hegde said that scientists do know that people tend to remember extremely happy or sad occasions vividly because of the emotional connection.

Extreme emotions trigger the release of a chemical in the brain called norepinephrine, which is related to adrenaline. That norepinephrine somehow helps memories last a long time – some even a lifetime.

In the current study, Hegde and colleagues looked at how norepinephrine helps female mice remember the scent of their male partners after being exposed to it just once during mating.

The researchers studied the neural circuitry in the accessory olfactory bulb, the part of the brain where memory of the male partner’s scent is stored.

They found that norepinephrine, released in mice while mating, activates an enzyme called Protein Kinase C (PKC), specifically, the “alpha” isoform of PKC, in the accessory olfactory bulb.

The PKC enzyme has about a dozen forms, or isoforms, that exist in the brains of mammals, including humans.

“The fact that PKC-alpha is activated through the release of norepinephrine is an important discovery. It explains how strong memories form for specific sensory experiences,” Hegde said.

In female mice, the information about the partner’s scent is carried by a chemical called glutamate and the fact that mating has occurred is conveyed by the release of norepinephrine, Hegde explained.

Previous studies have found that glutamate and norepinephrine together, but not individually, cause strong memory formation for the male’s scent.

“No one knew how this happened. Our findings indicate that the PKC-alpha enzyme tells the nerve cells in the brain that these two chemicals have arrived together. PKC-alpha is like the bouncer who lifts the rope blocking the entrance to an exclusive club for strong memories when glutamate and norepinephrine arrive together. If they arrive alone, they can’t get past the velvet rope,” Hegde said.

Hegde said that when memory is stored in the brain, the connections between nerve cells, called synapses, change. Strong memories are formed when synapses become stronger through structural changes that occur at the synapse. PKC-alpha works with glutamate and norepinephrine to create those changes.

The study is available online and is scheduled to appear in an upcoming issue of Neuroscience. (ANI)

Laughter is indeed the best medicine

Washington, Apr 17 (ANI): Laughter is indeed the best form of medicine – because it is good for the heart, says a new study.

In the research, “mirthful laughter” was linked to lower cholesterol and less risk of cardiovascular disease.

Lee Berk, a psychoneuroimmunologist, of Loma Linda University, and Dr. Stanley Tan, an endocrinologist and diabetes specialist at Oak Crest Health Research Institute in Loma Linda, examined the effects of mirthful laughter on 20 high-risk diabetic patients with hypertension and hyperlipidemia – an elevation of lipids in the bloodstream.

In the study, a group of 20 high-risk diabetic patients with hypertension and hyperlipidemia were divided into two groups: roup C (control) and Group L (laughter). Both groups were started on standard medications for diabetes (glipizide, TZD, metformin), hypertension (ACE inhibitor or ARB) and hyperlipidemia (statins).

The researchers then followed both groups for 12 months, testing their blood for the stress hormones epinephrine and norepinephrine; HDL cholesterol; inflammatory cytokines TNF-a FN-? and IL-6, which contribute to the acceleration of atherosclerosis and C-reactive proteins (hs-CRP), a marker of inflammation and cardiovascular disease.

Group L viewed self-selected humor for 30 minutes in addition to the standard therapies described above.

At the end of the time period, 26 percent of the laughter group had higher levels of high-density lipoprotein, the “good” cholesterol, compared to 3 percent in the control group. Harmful C-reactive proteins decreased 66 percent in the laughter group vs. 26 percent for the control group.

The findings were presented at the annual meeting of the American Physiological Society, part of the Experimental Biology 2009 gathering in New Orleans Convention. (ANI)

Why men like wet kisses with more ‘tongue action’

Washington, Feb 18 (ANI): When you share a kiss with your man, you reveal a lot more than just passion. US scientists have found that modern man uses smooch to pick up traces of estrogen in a woman’s saliva and thus gauge her fertility.

Anthropologist Helen Fisher of Rutgers University says that such behaviour may explain why men like wet kisses with more “tongue action”.

While at a meeting of the American Association for the Advancement of Science in Chicago, Fisher said that wet kisses could also be an unconscious attempt to transfer testosterone to the woman, which would stimulate her sexual interest.

“Men see kissing early in a relationship directly as a step to copulation,” she said.

According to Wendy Hill, a neuroscientist at Lafayette College in Easton, Pennsylvania, kissing may also serve as a way to assess the quality of a mate.

Fisher said that research has shown that the majority of men and women rate their first kiss as either “the kiss of death” or the blossoming of a new relationship.

The expert recently developed a personality test that measures four universal temperaments by using statistics from 40,000 people on the Internet dating site Chemistry.com.

Each temperament type was linked to activity levels of the brain chemicals dopamine/norepinephrine, serotonin, testosterone, and estrogen/oxytocin.

Fisher found that a person’s temperament guides which type of mate they select-boosting her belief that love involves some very powerful brain chemistry.

“People sing for love; they dance for love; they write about love; live for, kill, and die for love,” Fisher told National Geographic News.

“It’s a wonderful addiction when [a relationship is] working well-but perfectly horrible when it’s working poorly,” she added. (ANI)

Falling in love triggers chemical activity in the body

Washington, Feb 14 (ANI): When struck by cupid’s arrow our cheeks flush, palms sweat and hearts start racing, and scientists have now found the reason behind all these signs of love-chemical reactions in the body.

Loyola University Health System love guru Domeena Renshaw says that falling in love causes the body to release some chemicals that trigger specific physical reactions.

“Falling in love causes our body to release a flood of feel-good chemicals that trigger specific physical reactions. This internal elixir of love is responsible for making our cheeks flush, our palms sweat and our hearts race,” said Dr. Domeena Renshaw, author of Seven Weeks to Better Sex.

When two people fall in love, levels of substances, which include dopamine, adrenaline and norepinephrine, increase.

Dopamine creates feelings of euphoria while adrenaline and norepinephrine are responsible for the pitter patter of the heart, restlessness and overall preoccupation that go along with experiencing love.

MRI scans revealed that love lights up the pleasure centre of the brain.

When one falls in love, blood flow increases in this area, which is the same part of the brain responsible for drug addiction and obsessive-compulsive disorders.

“Love lowers serotonin levels, which is common in people with obsessive compulsive disorders. This may explain why we concentrate on little other than our partner during the early stages of a relationship,” said Renshaw.

Renshaw has warned that the physical responses to love may work to our disadvantage.

“The phrase ‘love is blind’ is a valid notion, because we tend to idealize our partner and see only things that we want to see in the early stages of the relationship. Outsiders have a much more objective and rational perspective on the partnership than the two people involved do,” said Renshaw.

There are three phases of love, which include lust, attraction and attachment.

Lust is a hormone-driven phase where we experience desire.

During the attraction phase, blood flow to the pleasure centre of the brain happens, when we feel an overwhelming fixation with our partner.

This behaviour fades during the attachment phase, when the body develops a tolerance to the pleasure stimulants.

Endorphins and hormones vasopressin and oxytocin also flood the body at this point creating an overall sense of well-being and security that is conducive to a lasting relationship. (ANI)

Fat cells’ interaction with brain may cast light on weight shedding process

Washington, February 6 (ANI): Georgia State University researchers have discovered that fat cells in the body work in the same fashion as a thermostat regulates temperature inside a house-giving feedback to the brain to regulate the process of fat burning.

C. Kay Song and Tim Bartness, who conducted this study in collaboration with Gary J. Schwartz of the Albert Einstein College of Medicine, say that their work may help advance the scientific understanding of how weight is shed.

The researchers found that during the process of burning fat, known as lipolysis, fat cells use sensory nerves to feed information to the brain.

The team revealed that they used viruses to trace communications in the nerves of Siberian hamsters, and found that the brain uses part of the nervous system used to regulate body functions, called the sympathetic nervous system, to in turn communicate back to the cells to initiate, continue or stop the fat burning depending upon the information the brain receives from the fat.

“The brain can trigger lipid burning by fat cells and through these sensory nerves, the fat cell can give the brain feedback. This is a really important concept in biology, as it can regulate the process of lipolysis much like how a thermostat regulates temperature in your house, using input from the air and output to a furnace or heating unit,” Bartness said.

“The presence and function of the sensory nerves has been completely ignored and the areas in the brain that receive this sensory information were unknown until we did these studies,” he added.

When the body has a low amount of a carbohydrate called glycogen, which acts as fuel for lipolysis, the body starts this process to release energy stored in fats.

Finally, nerves that are part of the sympathetic nervous system, a chemical called norepinephrine is released to trigger the breakdown of fat.

Bartness says that sensory nerves later inform the brain about the status of the lipolysis, communicating whether too much or too little energy has been released – and the activity of the sympathetic nerves can be adjusted accordingly.

“If you’re doing a moderate amount of exercise or even if it has been a fairly long interval since you last ate, you will use up all or most of the available glycogen, necessitating the break down fat to yield sufficient energy. But you don’t want to break down more than you need. So, this would be a way to stop the sympathetic nervous system from triggering the release of too much lipid energy from fat,” he said.

According to the researchers, though this communication process is known to play a role in the short-term burning of fat, it has yet to be determined whether this process is involved with the long-term issues of burning fat – important in understanding obesity and why some people burn fat more readily than others.

“It could be that sensory nerves have a dual function. In addition to the moment-to-moment lipolysis process, they might also have a longer term function. It’s complicated, and it might be a different subset of the sensory nerves performing the long-term monitoring of fat reserves,” he said.

The research appears in the American Journal of Physiology: Regulatory, Integrative and Comparative Physiology. (ANI)